Cephalosporin MIC creep among gonococci: Time for a pharmacodynamic rethink?

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2141-2148

  Chisholm, Stephanie A ^a   Mouton, Johan W ^b   Lewis, David A ^c,d   Nichols, Tom ^a   Ison, Catherine A ^a   Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cefixime; Ceftriaxone; Gonorrhoea; Neisseria gonorrhoeae

Indexed keywords

CEFIXIME; CEFTRIAXONE; PENICILLIN G;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE SURVEILLANCE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; EPSILOMETER TEST; GONORRHEA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MULTICENTER STUDY; NEISSERIA GONORRHOEAE; NONHUMAN; SINGLE DRUG DOSE; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ENGLAND; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; TIME FACTORS; WALES;

EID: 77957231790     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq289     Document Type: Article

References (52)

1. Van Slyke CJ, Arnold RC, Buchholtz M. Penicillin therapy in sulfonamide-resistant gonorrhea in men. Am J Public Health Nations Health 1943; 33: 1392-4.
2. Howie J. Gonorrhoea-a question of tactics. Br Med J 1979; 2: 1631-2.
3. Florey H. Clinical use of penicillin. Br Med Bull 1944; 2: 9-13.
4. Martin JE Jr, Lester A, Price EV et al. Comparative study of gonococcal susceptibility to penicillin in the United States, 1955-1969. J Infect Dis 1970; 122: 459-61.
5. Percival A, Rowlands J, Corkill JE et al. Penicillinase-producing gonococci in Liverpool. Lancet 1976; 2: 1379-82.
6. Centers for Disease Control and Prevention. Penicillinase-producing Neisseria gonorrhoeae. MMWR Morb Mortal Wkly Rep 1976; 33: 408-10.
7. Faruki H, Kohmescher RN, McKinney WP et al. A community-based outbreak of infection with penicillin-resistant Neisseria gonorrhoeae not producing penicillinase (chromosomally mediated resistance). N Engl J Med 1985; 313: 607-11.
8. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Year 2000 report. London: Health Protection Agency, 2001; Available via http://www.hpa.org.uk/Publications/InfectiousDiseases/HIVAndSTIs/0001GRASP2000/ (18 June 2010, date last accessed).
9. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Year 2008 report. London: Health Protection Agency, 2009. http://www.hpa.org.uk/Publications/InfectiousDiseases/HIVAndSTIs/0906GRASP2008/ (18 June 2010, date last accessed)
10. Centres for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2007 Supplement Gonococcal Isolate Surveillance Project (GISP) Annual Report 2007. Atlanta, GA, USA: Department of Health and Human Services Centres for Disease Control and Prevention, 2009.
11. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2006. Commun Dis Intell 2008; 32: 48-51.
12. Clinical Effectiveness Group, BASHH. National guideline on the diagnosis and treatment of gonorrhoea in adults 2005. http://www.bashh.org/documents/116/116.pdf (18 June 2010, date last accessed).
13. European Committee on Antimicrobial Susceptibility Testing. MIC Distributions for Tigecycline 2010. Available via http://www.eucast.org (18 June 2010, date last accessed).
14. The UK Collaborative Group for HIV and STI Surveillance. Testing Times. HIV and other Sexually Transmitted Infections in the United Kingdom 2007. London: Health Protection Agency, Centre for Infections, 2007.
15. Unemo M, Fasth O, Fredlund H et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009; 63: 1142-51.
16. Hardin JW, Cleves MA. sbe29: Generalized linear models: Extensions to the binomial family. Stata Technical Bulletin 50: 21-25. Stata Technical Bulletin Reprints 1999; 9: 140-6.
17. Faulkner RD, Bohaychuk W, Lanc RA et al. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother 1988; 21: 787-94.
18. Faulkner RD, Yacobi A, Barone JS et al. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J 1987; 6: 963-70.
19. Martin C, Ragni J, Lokiec F et al. Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery. Antimicrob Agents Chemother 1992; 36: 2804-7.
20. Meyers BR, Srulevitch ES, Jacobson J et al. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother 1983; 24: 812-4.
21. Goonetilleke AK, Dev D, Aziz I et al. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. J Antimicrob Chemother 1996; 38: 969-76.
22. Patel IH, Weinfeld RE, Konikoff J et al. Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother 1982; 21: 957-62.
23. Mouton JW, Schmitt-Hoffmann A, Shapiro S et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 2004; 48: 1713-8.
24. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005; 27:762-72.
25. Deguchi T, Yasuda M, Yokoi S et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9:35-9.
26. Vazquez JA, Martin E, Galarza P et al. In vitro susceptibility of Spanish isolates of Neisseria gonorrhoeae to cefditoren and five other antimicrobial agents. Int J Antimicrob Agents 2007; 29:473-4.
27. Tzelepi E, Daniilidou M, Miriagou V et al. Cluster of multidrug-resistant Neisseria gonorrhoeae with reduced susceptibility to the newer cephalo-porins in Northern Greece. J Antimicrob Chemother 2008; 62: 637-9.
28. Olsen B, Hadad R, Fredlund H et al. The Neisseria gonorrhoeae population in Sweden during 2005-phenotypes, genotypes and antibiotic resistance. APMIS 2008; 116: 181-9.
29. de Vries HJ, van der Helm JJ, Schim van der Loeff MF et al. Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. Euro Surveill 2009; 14: pii'19330. Available via http://www.eurosurveillance.org/viewarticle.aspx?articleid=19330 (22 June 2010, date last accessed).
30. Wang SA, Lee MV, O'Connor N et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001. Clin Infect Dis 2003; 37: 849-52.
31. Whiley DM, Limnios EA, Ray S et al. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007; 51: 3111-6.
32. Guoming L, Qun C, Shengchun W. Resistance of Neisseria gonorrhoeae epidemic strains to antibiotics: report of resistant isolates and surveillance in Zhanjiang, China: 1998 to 1999. Sex Transm Dis 2000; 27: 115-8.
33. Ameyama S, Onodera S, Takahata M et al. Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002; 46: 3744-9.
34. Zhao S, Duncan M, Tomberg J et al. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009; 53: 3744-51.
35. Lindberg R, Fredlund H, Nicholas R et al. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007; 51: 2117-22.
36. Lee SG, Lee H, Jeong SH et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010; 65: 669-75.
37. Jaffe HW, Schroeter AL, Reynolds GH et al. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 1979; 15: 587-91.
38. Ison CA, Mouton JW, Jones K et al. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004; 80: 386-8.
39. Handsfield HH, Dalu ZA, Martin DH et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994; 21: 107-11.
40. Chisholm SA, Neal TJ, Alawattegama AB et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009; 64: 353-8.
41. Palmer HM, Young H, Winter A et al. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother 2008; 62: 490-4.
42. Debuono BA, Opal SM, Sarafian SK et al. Analysis of an outbreak of penicillinase-producing Neisseria gonorrhoeae in Rhode Island, 1987. J Clin Microbiol 1989; 27: 2125-7.
43. Unemo M, Sjostrand A, Akhras M et al. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacin-resistant strain. APMIS 2007; 115: 231-41.
44. Tapsall JW, Ndowa F, Lewis DA et al. Meeting the public health challenge of multidrug-nd extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7: 821-34.
45. Wu DH. A review of the safety profile of cefixime. Clin Ther 1993; 15: 1108-19.
46. Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009; 85: 256-8.
47. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.
48. Workowski KA, Berman SM, Douglas JM. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148:606-13.
49. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 2006; 43 Suppl 2: S82-8.
50. Then RL, Sahl HG. Anti-infective strategies of the future: is there room for species-specific antibacterial agents? Curr Pharm Des 2010; 16: 555-66.
51. Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 2010; 11: 182-91.
52. Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008; 8: 574-81.